Akari Therapeutics (NASDAQ:AKTX) Earns Sell Rating from Analysts at StockNews.com
by Mitch Edgeman · The Markets DailyStockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
Shares of NASDAQ AKTX opened at $2.70 on Wednesday. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40. The company’s fifty day moving average is $3.34 and its two-hundred day moving average is $2.68.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Read More
- Five stocks we like better than Akari Therapeutics
- The How And Why of Investing in Oil Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- The Risks of Owning Bonds
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 10/7 – 10/11